© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
New kits on the blot—can we microarray the future of atherosclerosis?
Department of Internal Medicine, Mayo Clinic Rochester, 200 First Street S.W., Rochester, MN 55905, USA
*Tel.: +1-507-255-1296; fax: +1-507-255-1824. Email address: herrmann.joerg@mayo.edu
Received 30 July 2003; accepted 31 July 2003
| The first 150 words of the full text of this article appear below. |
See article by Martinet et al. [19] in this issue.
Cardiovascular diseases (CVDs) have a long track record, reaching pandemic proportions with the industrialization of the world. Current estimates of the World Health Organization project that, in less than 7 years from now, CVD will become the leading cause of death in developing countries and that, in less than 13 years from now, 25 million people will die from CVD on a global scale each year [1]. A major proportion of these CVD deaths will be related to atherosclerotic CVD (ASCVD) and, particularly, to its complication stage [2]. Hence, there is a strong call to the cardiovascular research community to identify pivotal mediators of atherosclerotic lesion formation and complication which at some point may turn into therapeutic targets.
What may be considered as searching for a needle in a haystack has been tremendously facilitated by the availability